Table 2.
Changes in clinical parameters during the patient follow-up (2019–2022).
| Main parameters | Before benralizumab (2019) | After benralizumab (to date) |
|---|---|---|
| Eosinophils (cell/μL) | 290 | 0 |
| Prednisolone (mg) | 20 | 5 |
| ACT (points) | 19 | 23 |
| CARAT (points) | 22 | 23 |
| Mini-AQLQ (points) | 3 | 4.7 |